Study:
A Phase I Study of Bevacizumab in Combination With SU11248
Rationale:
Monoclonal antibodies, such as bevacizumab, can block tumor growth in different
ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and
help kill them or carry tumor-killing substances to them. Sunitinib may stop the growth of
tumor cells by blocking some of the enzymes needed for cell growth. Bevacizumab and
sunitinib may also stop the growth of tumor cells by blocking blood flow to the tumor.
Giving bevacizumab together with sunitinib may kill more tumor cells.
Purpose:
This phase I trial is studying the side effects and best dose of bevacizumab and
sunitinib in treating patients with solid tumors.
Study Status: Active, not recruiting
Recruiting:
n/a
| Condition |
Intervention |
Phase |
|
Unspecified Adult Solid Tumor, Protocol Specific |
Biological: bevacizumab
Drug: sunitinib malate |
Phase 1 |
Verified by
Case Comprehensive Cancer Center
June, 2012
Sponsored by: Case Comprehensive Cancer Center
Information provided by: Case Comprehensive Cancer Center
ClinicalTrials.gov identifier: NCT00357318
Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
Cleveland, Ohio 44195
United States
Afshin Dowlati, MD., Principal Investigator
Brian Rini, MD., Principal Investigator